FIELD: biotechnology.
SUBSTANCE: present invention relates to production of human lipocaine muteins, which bind CD137, and can be used in medicine for therapy of cancer, infectious and autoimmune diseases. Mutant lipocaine is produced on the basis of mature lipocaine of human tear or mature lipocalin 2 (hNGAL). Produced muteins are also used in conjugates and fused proteins with a compound which prolongs the half-life of mutein in blood serum.
EFFECT: invention allows obtaining high-affinity to CD137 lipocaine muteins capable of breaking binding CD137L with CD137.
38 cl, 3 tbl, 9 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| METHODS FOR CELL CULTIVATION AND SETS AND DEVICE FOR THEM | 2016 |
|
RU2761557C2 |
| HUMAN LIPOLOCAL 2 MALLETES (LCN2, HNGAL) WITH AFFINITY FOR SPECIFIC TARGET | 2010 |
|
RU2707126C2 |
| HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY | 2019 |
|
RU2804336C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
